地高辛片治疗老年慢性心力衰竭对患者体内AngⅡ ANP MMP-9的变化研究

doi:10.3969/j.issn.1006-6233.2020.02.024

Abstract
Figure/Table
References
Related Citation (14)

Download: PDF (1237 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To analyze the effect of digoxin tablet on angiotensin Ⅱ (Ang Ⅱ) and atrial natriuretic peptide (ANP), matrix metalloprotease 9 (MMP-9) in elderly patients with chronic heart failure. Methods: 128 elderly patients with chronic heart failure were enrolled in our hospital from February 2015 to March 2018. They were divided into two groups according to different treatment methods. The control group was given routine treatment, the observation group was treated with digoxin tablets, and the clinical effect of the two groups was analyzed. Results: There was no significant difference in cardiac function, ang Ⅱ, ANP, MMP-9, TIMP-l, ET-1, cat and GSH PX between the two groups (P>0.05). The level of (53.26 ± 8.67) ng / l was lower than that of the control group (P<0.05). There was no significant difference between the observation group (9.38%) and the control group (4.69%) (P>0.05). Conclusion: Digoxin tablet can reduce the level of ANP, MMP-9, ang Ⅱ, improve the heart function, reduce the oxidative stress response, and does not increase the adverse reactions.

Key words： Chronic heart failure Digoxin tablets Angiotensin Ⅱ Matrix metalloproteinase 9

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHU Xiaoqin
	DENG Rensheng

Cite this article:

ZHU Xiaoqin,DENG Rensheng. Study on Changes of AngⅡ, ANP and MMP-9 in Elderly Patients with Chronic Heart Failure Treated with Digoxin Tablets[J]. HeBei Med, 2020, 26(2): 270-274.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2020.02.024 OR http://www.hbyxzzs.cn/EN/Y2020/V26/I2/270

[1] 沈红枫,夏海江.左卡尼汀注射液联合阿托伐他汀钙片治疗慢性心力衰竭的临床研究[J].中国临床药理学杂志,2017,33(5):395~397.
[2] 王智,张仲道,赵思鸿,等.地高辛与通心络胶囊联合治疗对慢性心力衰竭患者氧化应激、细胞因子及血管内皮功能的影响[J].海南医学院学报,2017,23(1):18~21.
[3] 陈波,赖晓惠,李东,等.慢性心力衰竭患者心室重塑及其相关血流动力学指标的变化[J].海南医学,2017,28(7):1041~1044.
[4] 李葆华,刘凌,肖纯,等.左卡尼汀口服液对慢性心力衰竭患者血清NT-proBNP、TNF-α、IL-6、MMP-9和心功能的影响[J].临床和实验医学杂志,2016,15(8):765~768.
[5] 李海涛,李彬,王艳艳,等.慢性心力衰竭水饮证与血浆ANP、AVP、尿AQP-2的相关性探讨[J].中西医结合心脑血管病杂志,2017,15(22):2925~2927.
[6] 刘志军,姜晓.2013年美国心脏病学会基金会和美国心脏协会心力衰竭指南解读[J].中华老年心脑血管病杂志,2014,16(1):109~110.
[7] 孔令刚.曲美他嗪对慢性心力衰竭患者内皮功能影响观察[J].现代仪器与医疗,2016,22(2):63~64.
[8] 高玉军,武会志,于海侠,等.心脏康复治疗对慢性心力衰竭患者NT-proBNP水平和生活质量的影响[J].河北医学,2019,25(9):1564~1567.
[9] Dougherty C M, Glenny R W, Burr R L, et al. A prospective randomized trial of moderately strenuous aerobic exercise after an implantable cardioverter defibrillator (ICD).[J]. Circulation, 2016, 131(21):1835~42.
[10] 吴勇进,李玲.不同心功能分级慢性心力衰竭患者血清BNP、TNF-α、MMP-9、IL-6检测的临床价值探讨[J].国际检验医学杂志,2016,37(7):904~906.
[11] 王刚,曹永涛,傅秀慧,等.慢性心力衰竭患者检测血清基质金属蛋白酶组织抑制物、可溶性E-选择素的意义[J].内科急危重症杂志,2017,23(6):490~491,503.